Skip to main content

Table 1 Baseline characteristics of subjects by follow up status

From: Common genetic polymorphisms of microRNA biogenesis pathway genes and breast cancer survival

 

Disease-free survival (n = 480)

Overall survival (n = 488)

 

Relapse (n = 90)a

No relapse (n = 389)

HR (95% CI)

P

aHR (95% CI) b

P

Death (n = 41)

Alive (n = 447)

HR (95% CI)

P

aHR (95% CI) c

P

Follow up duration, years (median)

0.12-8.34 (4.64)

    

0.18-9.45 (6.24)

    

Age (mean(SD))

46.3 (12.5)

46.6 (10.6)

0.99 (0.97- 1.01)

0.470

1.00 (0.98- 1.02)

0.918

45.8 (13.8)

46.8 (10.7)

0.98 (0.96- 1.01)

0.289

0.99 (0.97- 1.02)

0.632

Tumor size

            

 ≤2 cm 

27 (30.0)

210 (55.1)

1 (reference)

 

1 (reference)

 

10 (21.7)

229 (52.9)

1 (reference)

 

1 (reference)

 

 >2 cm

63 (70.0)

171 (44.9)

2.49 (1.59- 3.91)

<.001

1.66 (1.01- 2.72)

0.045

36 (78.3)

204 (47.1)

3.73 (1.85- 7.52)

<.001

2.20 (1.03- 4.67)

0.041

Lymph-node involvement

            

 No 

36 (40.0)

258 (67.5)

1 (reference)

 

1 (reference)

 

15 (32.6)

282 (65.0)

1 (reference)

 

1 (reference)

 

 Yes 

54 (60.0)

124 (32.5)

3.00 (1.97- 4.58)

<.001

2.54 (1.60- 4.03)

<.001

31 (67.4)

152 (35.0)

3.86 (2.08- 7.16)

<.001

2.70 (1.40- 5.20)

0.003

Metastasis

            

 No 

90 (100)

389 (100)

-

-

-

-

42 (91.3)

432 (99.1)

1 (reference)

 

1 (reference)

 

 Yes 

      

4 (8.7)

4 (0.9)

7.15 (2.55-20.02)

<.001

5.26 (1.71-16.15)

0.004

Histologic grade

            

 I-II 

23 (30.7)

207 (61.4)

1 (reference)

 

1 (reference)

 

12 (31.6)

221 (58.3)

1 (reference)

 

1 (reference)

 

 III 

52 (69.3)

130 (38.6)

3.00 (1.84- 4.90)

<.001

3.40 (1.74- 6.64)

<.001

26 (68.4)

158 (41.7)

2.81 (1.42- 5.56)

0.003

1.93 (0.93- 4.03)

0.078

Nuclear grade

            

 I-II 

21 (40.4)

146 (59.4)

1 (reference)

 

1 (reference)

 

8 (34.8)

160 (57.1)

1 (reference)

 

1 (reference)

 

 III 

31 (59.6)

100 (40.7)

1.82 (1.05- 3.17)

0.034

0.59 (0.28- 1.23)

0.161

15 (65.2)

120 (42.9)

2.52 (1.07- 5.94)

0.035

1.12 (0.40- 3.11)

0.830

Estrogen receptor

            

 Positive 

49 (55.1)

238 (63.0)

1 (reference)

 

1 (reference)

 

22 (48.9)

269 (62.9)

1 (reference)

 

1 (reference)

 

 Negative 

40 (44.9)

140 (37.0)

1.33 (0.88- 2.03)

0.177

1.69 (0.79- 3.62)

0.177

23 (51.1)

159 (37.2)

1.82 (1.02- 3.28)

0.044

1.02 (0.37- 2.80)

0.975

Progesterone receptor

            

 Positive 

42 (47.7)

202 (53.6)

1 (reference)

 

1 (reference)

 

18 (40.0)

230 (54.0)

1 (reference)

 

1 (reference)

 

 Negative

46 (52.3)

175 (46.4)

1.23 (0.81- 1.87)

0.331

1.53 (0.79- 2.96)

0.202

27 (60.0)

196 (46.0)

1.75 (0.96- 3.18)

0.066

1.14 (0.48- 2.73)

0.765

Adjuvant chemotherapy

            

 Yes 

78 (88.6)

285 (76.0)

1 (reference)

 

1 (reference)

 

41 (91.1)

327 (76.9)

1 (reference)

 

1 (reference)

 

 No 

10 (11.4)

90 (24.0)

0.47 (0.24- 0.91)

0.026

1.00 (0.47- 2.14)

0.996

4 (8.9)

98 (23.1)

0.36 (0.13- 1.00)

0.049

1.16 (0.37- 3.60)

0.804

Hormone receptor therapy

            

 Yes 

47 (52.8)

263 (70.1)

1 (reference)

 

1 (reference)

 

21 (46.7)

292 (68.5)

1 (reference)

 

1 (reference)

 

 No 

42 (47.0)

112 (29.9)

1.79 (1.18- 2.71)

0.006

2.43 (1.17- 5.07)

0.018

24 (53.3)

134 (31.5)

2.33 (1.30- 4.18)

0.005

1.51 (0.80- 2.85)

0.201

Radiotherapy

            

 Yes 

43 (48.9)

185 (49.7)

1 (reference)

 

1 (reference)

 

20 (43.5)

211 (50.0)

1 (reference)

 

1 (reference)

 

 No 

45 (51.1)

187 (50.3)

0.90 (0.59- 1.37)

0.633

0.96 (0.62- 1.48)

0.843

26 (56.5)

211 (50.0)

1.10 (0.61- 1.97)

0.760

1.12 (0.61- 2.04)

0.723

  1. NOTE Column frequency may be less than total number of subjects due to missing values.
  2. a Disease free survival event (relapse) included locoregional recurrence (n=76), 2nd primary cancer (n=11), and death (n=3) from any cause.
  3. b Adjusted for age, tumor size (≤2cm and >2cm), lymph-node involvement (no and yes), histologic grade (I-II and III), nuclear grade (I-II and III) and ER status (positive and negative), PR status (positive and negative) and hormone receptor therapy (yes and no.).
  4. c Adjusted for age, tumor size (≤2cm and >2cm), lymph-node involvement (no and yes), metastasis (no and yes), histologic grade (I-II and III), and hormone receptor therapy (yes and no).
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us